Immunovant appoints Eric Venker as CEO, Girao as CFO

Immunovant (IMVT) announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE. Eric Venker, M.D., Roivant’s (ROIV) President and an Immunovant Director, has been appointed as Immunovant’s CEO. Dr. Venker brings over two decades of clinical practice and operational experience to the company and will continue to serve on Immunovant’s Board of Directors. As part of this planned transition, Pete Salzmann, M.D. retired from his position as Immunovant CEO and Director. Renee Barnett stepped down from her position as Immunovant CFO; she is succeeded by Tiago Girao, formerly Telavant CFO. Immunovant has announced these changes in conjunction with a broader strategic transition as development activities begin to conclude for batoclimab and ramp up for IMVT-1402, with increased Roivant alignment and the announcement of two additional indications today. Additionally, IND was cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025